Application of Danshen composition in preparation of medicine for secondary prevention of coronary heart disease

一种二级预防、组合物的技术，应用在药物组合、心血管系统疾病、羟基化合物有效成分等方向

Active Publication Date: 2015-08-19
TIANJIN TASLY PHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its main side effect is bleeding, therefore, it cannot be used in patients with coagulation disorders, ulcer diseases, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Danshen composition in preparation of medicine for secondary prevention of coronary heart disease
  • Application of Danshen composition in preparation of medicine for secondary prevention of coronary heart disease
  • Application of Danshen composition in preparation of medicine for secondary prevention of coronary heart disease

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0187] Recipe dosage

[0188] Danshen 45.0g Panax notoginseng 47.0g Borneol 0.1g

[0189] Excipient polyethylene glycol-6000 18g

[0190] Make 1000 drop pills

[0191] Extraction of Danshen and Panax notoginseng

[0192] Take coarsely crushed Danshen medicinal materials (45.0g) and Panax notoginseng medicinal materials (47.0g) into the extraction tank, add 5 times the amount of water of the above crude drugs, decoct for 2 hours, filter, add 4 times the amount of water to the filter residue, and decoct The second extraction was carried out in 1 hour, filtered, the filter residue was discarded, and the filtrates were combined. The filtrate is concentrated under reduced pressure to a ratio of 1: 0.9-1.1 between the volume of the medicinal solution (L) and the weight (Kg) of the medicinal material, and slowly adds 95% (v / v) ethanol to make the alcoholic concentration of the medicinal solution at 69-71% ( v / v), let stand for 12 hours. The supernatant of the medicinal solution ...

preparation Embodiment 2

[0198] Take 70.0g Salvia miltiorrhiza and 13.7g Panax notoginseng, crush them, put them into an extraction tank, add 5 times the amount of water of the crude drug above, extract for 2 hours, filter, and collect the primary filtrate. Add 4 times the amount of water to the dregs, decoct for 1 hour, filter, mix with the filtrate extracted for the first time, and concentrate under reduced pressure until the ratio of solution volume (L) to crude drug mass (Kg) is 1:0.9-1.1. Add 95% (v / v) ethanol until the alcohol content reaches 69-71% (v / v), let stand for 12 hours, and filter. The filtrate is concentrated into an extract with a relative density of 1.32-1.40.

[0199] Mix the above extract with 0.8g borneol and 15.5g polyethylene glycol 6000, heat at 85°C, mix for 30 minutes, transfer to the dropping pill machine, keep warm at 80°C, drop into liquid paraffin at 7°C, take out the dropping pills, remove Liquid paraffin, that is.

[0200] Dropping pills are reddish-brown pills, unif...

preparation Embodiment 3

[0202] Take 96.0g Danshen, 1.0g Panax notoginseng, 3.0g borneol and 20g polyethylene glycol 6000 respectively. The extraction method was the same as that in Preparation Example 1; except for the following parameters, the temperature of the dropping pill machine was 64° C., and the temperature of the liquid paraffin was 0° C., and the method in Preparation Example 1 was used to prepare the dropping pills.

[0203] Dropping pills are reddish-brown pills, uniform in size, smooth, fragrant and slightly bitter. The pellet weight was 25mg±15%, and the diameter was 3.34±15%mm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

Description

technical field [0001] The invention relates to the use of compound medicine in the prevention of coronary heart disease, in particular to the use of traditional Chinese medicine compound medicine in the prevention of coronary heart disease. Background technique [0002] Coronary atherosclerotic heart disease refers to coronary atherosclerosis that narrows or blocks the blood vessel lumen, or (and) causes myocardial ischemia, hypoxia or necrosis due to functional changes (spasm) of coronary arteries It is collectively referred to as coronary heart disease (coronary heart disease), referred to as coronary heart disease, also known as ischemic heart disease (ischemic heart disease). Coronary atherosclerotic heart disease is the most common type of organ lesions caused by atherosclerosis, and it is also a common disease that seriously endangers human health. The vast majority of coronary heart disease is caused by coronary atherosclerosis. The incidence of coronary heart dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/53A61K36/258A61K31/045A61P9/00A61P9/10
CPCA61K45/06A61K31/616A61K31/045A61K36/537A61K36/258A61P17/00A61P43/00A61P9/00A61P9/06A61P9/10A61P3/10A61K2300/00
Inventor 闫希军吴迺峰闫凯境孙鹤郭治昕祝国光刘巍巍赵利斌罗瑞芝
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap